The impact of sugammadex versus neostigmine reversal on return to intended oncological therapy-related outcomes after breast cancer surgery: a retrospective cohort study
Authors' conclusion
The administration of sugammadex, compared with neostigmine, is not associated with significant improvements in RIOT-related variables after breast cancer surgery.
Study context
- Population
- Women ≥ 18 years requiring mastectomy for nonmetastatic breast cancer resection, 2015 to 2022
- Participants
- 888 women
- Exposure
- Sugammadex vs neostigmine reversal
- Sugammadexn = 569
- Neostigminen = 319reference
- Outcome
- RIOT-related outcomes: time to RIOT, incidence of RIOT at 90 and 180 days, length of hospital stay, 30-day hospital readmission
Methodological detailsmultivariate analysis
- Multivariate analysis
Main finding
As reported in the abstract
RIOT at 90 days · 90 days
P < 0.001
Observational data: associations, not effects.
Further findings
RIOT at 180 days
P < 0.001
| Outcome | Estimate | P value |
|---|---|---|
| Time to RIOTSugammadex achieved RIOT faster | 37 days (95% CI 35–41) | P < 0.001 |
Original publication
The impact of sugammadex versus neostigmine reversal on return to intended oncological therapy-related outcomes after breast cancer surgery: a retrospective cohort study. Perioper Med (Lond). Published 2 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →